Abstract
Phosphofructokinase deficiency (Tarui disease, glycogen storage disease VII, GSD VII) stands out among all the GSDs. PFK deficiency was the first recognized disorder that directly affects glycolysis. Ever since the discovery of the disease in 1965, a wide range of biochemical, physiological and molecular studies of the disorder have greatly expanded our understanding of the function of normal muscle, general control of glycolysis and glycogen metabolism. The studies of PFK deficiency vastly enriched the field of glycogen storage diseases, as well as the field of metabolic and neuromuscular disorders. This article cites a historical overview of this clinical entity and the progress that has been made in molecular genetic area. We will also present the results of a search in-silico, which allowed us to identify a previously unknown sequence of the human platelet PFK gene (PFK-P). In addition, we will describe phylogenetic analysis of evolution of PFK genes.
Keywords: phosphofructokinase deficiency, tarui disease, glycogen storage disease Vll(gsd Vll)
Current Molecular Medicine
Title: Phosphofructokinase Deficiency Past, Present and Future
Volume: 2 Issue: 2
Author(s): Hiromu Nakajima, Nina Raben, Tomoya Hamaguchi and Tomoyuki Yamasaki
Affiliation:
Keywords: phosphofructokinase deficiency, tarui disease, glycogen storage disease Vll(gsd Vll)
Abstract: Phosphofructokinase deficiency (Tarui disease, glycogen storage disease VII, GSD VII) stands out among all the GSDs. PFK deficiency was the first recognized disorder that directly affects glycolysis. Ever since the discovery of the disease in 1965, a wide range of biochemical, physiological and molecular studies of the disorder have greatly expanded our understanding of the function of normal muscle, general control of glycolysis and glycogen metabolism. The studies of PFK deficiency vastly enriched the field of glycogen storage diseases, as well as the field of metabolic and neuromuscular disorders. This article cites a historical overview of this clinical entity and the progress that has been made in molecular genetic area. We will also present the results of a search in-silico, which allowed us to identify a previously unknown sequence of the human platelet PFK gene (PFK-P). In addition, we will describe phylogenetic analysis of evolution of PFK genes.
Export Options
About this article
Cite this article as:
Nakajima Hiromu, Raben Nina, Hamaguchi Tomoya and Yamasaki Tomoyuki, Phosphofructokinase Deficiency Past, Present and Future, Current Molecular Medicine 2002; 2 (2) . https://dx.doi.org/10.2174/1566524024605734
DOI https://dx.doi.org/10.2174/1566524024605734 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prevention and treatment of atherosclerosis with flaxseed -derived compound secoisolariciresinol diglucoside
Current Pharmaceutical Design Therapeutic Modulation of Growth Factors and Cytokines in Regenerative Medicine
Current Pharmaceutical Design Overview of Current and Upcoming Strategies Implied for the Therapy of Type 2 Diabetes Mellitus
Current Diabetes Reviews EDITORIAL (Thematic Issue: Retinal Neurodegeneration in the Course of Diabetes: Neuroprotection as a Potential Treatment Target)
Current Neuropharmacology Bariatric Surgery: Indications, Safety and Efficacy
Current Pharmaceutical Design Phytochemicals from Peanut (<i>Arachis hypogaea</i> L.) Skin Extract with Potential for Pharmacological Activity
Current Bioactive Compounds Relevance of Dyslipidaemia and its Consequences in Periodontal Patients with Co-Existing Cardiovascular Disease and Diabetes Mellitus: Therapeutic Targets
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry Oxidative Stress in Alzheimer Patients in Different Stages of the Disease
Current Medicinal Chemistry Effects of Atorvastatin on Cerebral Blood Flow in Middle-Aged Adults at Risk for Alzheimer’s Disease: A Pilot Study
Current Alzheimer Research Free Radicals Generated by Post-Prandial Oxidative Burst in the Early Alterations of Vascular Contractility
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Does Handle Region Peptide Provide Benefits in Chronic Kidney Disease?
Current Hypertension Reviews Transient Tachypnea of the Newborn: The Treatment Strategies
Current Pharmaceutical Design Mediterranean Diet, Brain and Muscle: Olive Polyphenols and Resveratrol Protection in Neurodegenerative and Neuromuscular Disorders
Current Medicinal Chemistry Ghrelin: A Gastric Peptide that Regulates Hypothalamic Control of Feeding
Current Medicinal Chemistry - Central Nervous System Agents Novel Treatments in Diabetic Nephropathy
Current Hypertension Reviews Adrenal Hyperandrogenism and Polycystic Ovary Syndrome
Current Pharmaceutical Design Mechanisms of Renal Microvascular Dysfunction in Type 1 Diabetes: Potential Contribution to End Organ Damage
Current Vascular Pharmacology Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research Cardiovascular Complications in Patients with Turner’s Syndrome
Current Pharmaceutical Design